Budd-Chiari Syndrome: Pathophysiology, Risk Factors, and Management

Definition and Pathophysiology

• Budd-Chiari syndrome is defined as obstruction of hepatic venous outflow that can be located anywhere from the small hepatic venules up to the entrance of the inferior vena cava (IVC) into the right atrium, according to the Journal of Hepatology 1
• The pathophysiological consequences of Budd-Chiari syndrome include venous obstruction leading to sinusoidal congestion 2, hepatic ischemia 3, hepatocellular necrosis 2, and potential progression to centrilobular fibrosis, nodular regenerative hyperplasia, and/or cirrhosis 1

Risk Factors

• Myeloproliferative neoplasms are a common cause of Budd-Chiari syndrome, with a prevalence of approximately 49% of cases, and include polycythemia vera and essential thrombocytosis, as reported in Hepatology 4
• Inherited thrombophilias, such as Factor V Leiden mutation, protein C deficiency, protein S deficiency, antithrombin deficiency, and prothrombin G20210A gene variant, are also risk factors for Budd-Chiari syndrome 1, 4, 5
• Malignancies, paroxysmal nocturnal hemoglobinuria, antiphospholipid antibodies, and intra-abdominal inflammatory conditions are additional risk factors for Budd-Chiari syndrome 1, 4

Clinical Presentation and Symptoms

• The clinical presentation of Budd-Chiari syndrome is heterogeneous, ranging from asymptomatic to fulminant hepatic failure, as described in the Journal of Hepatology and Hepatology 1, 3
• Common symptoms and signs of Budd-Chiari syndrome include ascites, present in 83% of patients at diagnosis 1, hepatomegaly, present in 67% of patients 1, abdominal pain 1, intractable ascites 4, and rapidly progressive liver failure 3, 4

Diagnostic Approach

• Doppler ultrasound is the first-line investigation for Budd-Chiari syndrome, with a diagnostic sensitivity >75%, as recommended by the Journal of Hepatology 1
• MRI/CT, venography, and liver biopsy are additional diagnostic tools used to confirm the diagnosis of Budd-Chiari syndrome 1
• Thrombophilia screening, including protein S, protein C, antithrombin levels, Factor V Leiden mutation, prothrombin G20210A gene variant, and antiphospholipid antibodies, is essential for diagnosing Budd-Chiari syndrome 1
• Testing for myeloproliferative neoplasms, including JAK2V617F mutation testing, calreticulin mutation screening, and bone marrow histology, is also crucial for diagnosing Budd-Chiari syndrome 1

Management Considerations

• Anticoagulation should be started as soon as possible and continued indefinitely to reduce the risk of clot extension and new thrombotic episodes, as recommended by the Journal of Hepatology 1, 2
• Treatment of underlying conditions, particularly myeloproliferative disorders, is essential for managing Budd-Chiari syndrome 1
• Invasive interventions, such as angioplasty/stenting, transjugular intrahepatic portosystemic shunts (TIPS), and liver transplantation, may be necessary for patients with Budd-Chiari syndrome 2, 5, 6

Budd-Chiari Syndrome and Varices

Clinical Evidence and Management

• Variceal bleeding during pregnancy occurred in three women with Budd-Chiari syndrome, none of whom had received appropriate primary prophylaxis 7
• Ectopic varices can also develop, with a high rate of recurrent bleeding (42% within 48 hours after TIPS) despite hemodynamic correction 8, 9
• Primary prophylaxis with beta-blockers or endoscopic variceal ligation for high-risk varices is recommended, following the same guidelines as for cirrhosis, as suggested by the European Association for the Study of the Liver 9
• TIPS consideration is recommended for recurrent variceal bleeding despite adequate endoscopic and medical treatment, as per the American Association for the Study of Liver Diseases guidelines 8, 9

Diagnostic and Management Implications

• The presence of esophageal varices is a significant predictor of major bleeding in Budd-Chiari syndrome patients, emphasizing the need for careful management, according to the American College of Gastroenterology 9

Portal Hypertension in Budd-Chiari Syndrome

Pathophysiological Mechanism

• Budd-Chiari syndrome represents post-sinusoidal (post-hepatic) portal hypertension, distinguishing it from cirrhotic portal hypertension which is primarily sinusoidal, as noted by the American Association for the Study of Liver Diseases 10
• The liver parenchyma may initially be relatively preserved despite severe portal hypertension, according to the American College of Radiology 10, 11

Treatment and Management

• Interventions that restore hepatic venous drainage, such as angioplasty or TIPS, can be more effective than in cirrhotic portal hypertension, as reported by the European Society of Gastrointestinal Endoscopy 12
• The natural history and response to treatment differ from cirrhotic causes, as stated by the American Association for the Study of Liver Diseases 10

Budd-Chiari Syndrome and Inferior Mesenteric Vein Varix

Pathophysiological Mechanism

• Budd-Chiari syndrome creates post-sinusoidal portal hypertension by obstructing hepatic venous outflow, leading to sinusoidal congestion and increased portal pressure, which forces blood to seek alternative drainage pathways through collateral vessels, including the development of portosystemic collaterals, such as varices in the esophagus, stomach, and mesenteric venous system, as recommended by the European Association for the Study of the Liver 13, 14
• The inferior mesenteric vein becomes engorged, forming varices, as it serves as a collateral pathway when normal hepatic venous drainage is blocked, according to the National Comprehensive Cancer Network 15
• Esophageal varices occur in 58% of Budd-Chiari patients, demonstrating the high prevalence of variceal complications, as reported by the European Association for the Study of the Liver 13, 14

Clinical Evidence for Mesenteric Involvement

• Approximately 15% of Budd-Chiari patients have simultaneous portal vein thrombosis at presentation, as reported by the European Association for the Study of the Liver 13, 14
• Splanchnic vein thrombosis, including mesenteric veins, is a recognized complication, particularly in patients with underlying myeloproliferative neoplasms, according to the American Society of Clinical Oncology 16
• The JAK2V617F mutation is found in approximately 45% of Budd-Chiari patients and 34% of those with portal vein thromboses, as reported by the American Society of Clinical Oncology 16

Clinical Implications and Management

• Anticoagulation should be initiated immediately and continued indefinitely to prevent clot extension and new thrombotic episodes, even in the presence of varices, as recommended by the European Association for the Study of the Liver 13, 14
• Treatment of underlying myeloproliferative disorder with hydroxyurea or interferon-alpha to normalize blood counts and maintain hematocrit <45% in polycythemia vera is recommended by the European Association for the Study of the Liver 13, 14

Pathophysiology and Clinical Implications of Ascitic Fluid Protein Changes in Budd-Chiari Syndrome

Diagnostic Considerations

• High protein ascites (>2.5 g/dL) with high SAAG should immediately raise suspicion for acute or early Budd-Chiari syndrome, with the American Association for the Study of Liver Diseases recommending immediate diagnostic evaluation 17

Management Priorities

• The European Association for the Study of the Liver recommends anticoagulation therapy to be initiated immediately upon Budd-Chiari syndrome diagnosis and continued indefinitely, regardless of ascitic fluid protein content or presence of varices, with a strength of evidence level of 1A 17